Insulin syringe maker Embecta's Q4 revenue just misses estimates

Reuters
2025/11/25
Insulin syringe maker Embecta's Q4 revenue just misses estimates

Overview

  • Embecta Q4 revenue misses analyst expectations, down 7.7% yr/yr

  • Adjusted EBITDA for Q4 beats analyst estimates, indicating strong operational performance

  • Company announces quarterly dividend of $0.15 per share

Outlook

  • Embecta expects fiscal 2026 revenue between $1,071 mln and $1,093 mln

  • Company anticipates fiscal 2026 EPS of $2.80 to $3.00

  • Embecta sees fiscal 2026 adjusted operating margin of 29% to 30%

Result Drivers

  • ADVANCED ORDERING IMPACT - Revenue decline attributed to advanced distributor ordering in previous quarters and ongoing business dynamics in China

  • PROFITABILITY IMPROVEMENT - Higher GAAP operating margin and net income year over year, exceeding adjusted operating and EBITDA margin ranges

  • DEBT REDUCTION - Focus on operational efficiency and restructuring led to accelerated debt reduction and increased financial flexibility

Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q4 Revenue

Slight Miss*

$264 mln

$265.69 mln (4 Analysts)

Q4 Adjusted EPS

Miss

$0.50

$0.54 (3 Analysts)

Q4 Net Income

$26.40 mln

Q4 Adjusted EBITDA

Beat

$89.90 mln

$79.50 mln (3 Analysts)

Q4 Adjusted Operating Income

Beat

$66.70 mln

$63.75 mln (3 Analysts)

Q4 Adjusted Gross Profit

$159.50 mln

Q4 Dividend

$0.15

Q4 Gross Profit

$158.50 mln

Q4 Operating Income

$56.50 mln

*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage

  • The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 2 "hold" and 1 "sell" or "strong sell"

  • The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."

  • Wall Street's median 12-month price target for Embecta Corp is $14.00, about 4.6% below its November 24 closing price of $14.64

  • The stock recently traded at 5 times the next 12-month earnings vs. a P/E of 4 three months ago

Press Release: ID:nGNXbrZwx5

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10